Additional Listing and total voting rights

Released : 28/09/2018 16:35

RNS Number : 4076C

M&C Saatchi PLC

28 September 2018

 

M&C Saatchi PLC

28 September 2018

 

M&C Saatchi PLC ("M&C Saatchi" or "the Company")

 

Additional Listing and Total Voting Rights

 

Application has been made to the London Stock Exchange for the Admission of 315,681 new ordinary shares of 1p each in the Company (the "New Shares") to trading on AIM. The New Shares have been issued as final payment for put option consideration for an additional 24.5% stake in its US subsidiary LIDA NY LLP, the acquisition of which was announced on 16 March 2016.

Admission of the New Shares is expected to become effective on 2 October 2018.

 

The total number of Ordinary Shares in issue on the date of admission will be 87,088,606. Of this total, 700,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares in issue with voting rights will be 86,388,606.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.

 

-ends-

 

For further information, please contact:

 

M&C Saatchi plc                                 +44 (0) 207 544 3693  

Andy Blackstone, Company Secretary                        

                                                            

Numis Securities                                +44 (0) 207 260 1000  

Nick Westlake, NOMAD                                        

Charles Farquhar, Corporate Broking                        

                                                            

Tulchan Communications                  +44 (0) 207 353 4200  

Tom Murray

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END